¼¼°èÀÇ ¼¼Æ÷Ä¡·á ½ÃÀå
Cell Therapy
»óǰÄÚµå : 1650989
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 263 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,020,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,062,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¼¼Æ÷Ä¡·á ½ÃÀåÀº 2030³â±îÁö 421¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 191¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¼¼Æ÷Ä¡·á ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 14.1%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 421¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ µ¿Á¾ÀÌ°è ¼¼Æ÷Ä¡·á´Â CAGR 12.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 234¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÚ°¡ ¼¼Æ÷Ä¡·á ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 15.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 53¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¼¼Æ÷Ä¡·á ½ÃÀåÀº 2024³â¿¡ 53¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 65¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 13.5%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 12.1%¿Í 11.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 10.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¼¼Æ÷Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¼¼Æ÷Ä¡·á°¡ Çö´ë ÀÇÇÐÀÇ ÆÇµµ¸¦ ¹Ù²Ü ¼ö ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¼¼Æ÷Ä¡·á´Â ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ÅðÇ༺ ÁúȯÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ°í ¼Õ»óµÈ Á¶Á÷À» Ä¡·áÇÏ°í º¹±¸Çϱâ À§ÇØ ½Åü ÀÚüÀÇ ¼¼Æ÷¸¦ »ç¿ëÇÔÀ¸·Î½á ÀÇ·á ºÐ¾ß¸¦ ȹ±âÀûÀ¸·Î ÀçÆíÇϰí ÀÖ½À´Ï´Ù. Áõ»óÀ» ¾ïÁ¦ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃá ±âÁ¸ Ä¡·á¹ý°ú ´Þ¸®, ¼¼Æ÷Ä¡·á´Â ƯÁ¤ »ý¹°ÇÐÀû ¸ÞÄ¿´ÏÁòÀ» Ç¥ÀûÀ¸·Î »ïµµ·Ï Á¶ÀÛÇϰųª äÃëÇÒ ¼ö ÀÖ´Â »ì¾ÆÀÖ´Â ¼¼Æ÷¸¦ ÀÌ¿ëÇÏ¿© Áúº´ÀÇ ±Ùº» ¿øÀÎÀ» ÇØ°áÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î CAR-T Ä¡·á´Â Á¾¾çÇп¡¼­ ȹ±âÀûÀÎ Ä¡·á¹ýÀ¸·Î, ȯÀÚÀÇ T¼¼Æ÷¸¦ À¯Àü°øÇÐÀûÀ¸·Î Á¶ÀÛÇÏ¿© ¾Ï¼¼Æ÷¸¦ ã¾Æ ÆÄ±«ÇÏ´Â Ä¡·á¹ýÀÔ´Ï´Ù. ÀÌ Ä¡·á¹ýÀº ÀÌ¹Ì ÀϺΠÇ÷¾×¾Ï Ä¡·á¿¡¼­ °ý¸ñÇÒ ¸¸ÇÑ ¼º°øÀ» °ÅµÎ¾úÀ¸¸ç, ´Ù¸¥ ¾ÏÁ¾À¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. Àç»ýÀÇÇп¡¼­´Â ½ÉÀ庴, ½Å°æÅðÇ༺ Áúȯ, ´ç´¢º´ µîÀ¸·Î ¼Õ»óµÈ Á¶Á÷À» º¹±¸Çϱâ À§ÇØ Áٱ⼼Æ÷°¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á´Â °³ÀÎ ¸ÂÃãÇü Ä¡·áÀÇ Å« µµ¾àÀ» ÀǹÌÇϸç, °ú°Å¿¡´Â Ä¡·á°¡ ºÒ°¡´ÉÇÏ´Ù°í ¿©°ÜÁ³´ø Áúº´À» ¾Î°í Àִ ȯÀڵ鿡°Ô Èñ¸ÁÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¿¬±¸°¡ ÁøÇàµÊ¿¡ µû¶ó ¼¼Æ÷Ä¡·á´Â ȯÀÚ °íÀ¯ÀÇ À¯ÀüÀÚ¿Í ¼¼Æ÷ ±¸¼º¿¡ µû¶ó ¸ÂÃãÇü Ä¡·á¸¦ Á¦°øÇÏ´Â ¸ÂÃãÇü ÀÇ·áÀÇ ¹Ì·¡ Áß½ÉÃàÀ¸·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

¼¼Æ÷Ä¡·á´Â º¹ÀâÇÑ Áúº´ÀÇ Ä¡·á¹ýÀ» ¾î¶»°Ô º¯È­½Ãų °ÍÀΰ¡?

¼¼Æ÷Ä¡·á´Â ±âÁ¸ Ä¡·á¹ý¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â º¹ÀâÇÑ Áúº´À» Ä¡·áÇÏ´Â µ¥ ÇʼöÀûÀ̸ç, Ä¡·á °³ÀÔÀÇ »õ·Î¿î ±æÀ» Á¦°øÇÕ´Ï´Ù. Á¾¾çÇÐ ºÐ¾ß¿¡¼­ CAR-T Ä¡·á¿Í °°Àº ¼¼Æ÷ ±â¹Ý Ä¡·á´Â ȯÀÚ ÀÚ½ÅÀÇ ¸é¿ª¼¼Æ÷¸¦ »ç¿ëÇÏ¿© ¾Ï¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î »ï¾Æ ¾Ï¼¼Æ÷¸¦ Á×ÀÓÀ¸·Î½á ¾Ï Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ÀÌ °íµµ·Î °³ÀÎÈ­µÈ Ä¡·á Á¢±Ù¹ýÀº ¹éÇ÷º´À̳ª ¸²ÇÁÁ¾°ú °°Àº ¾Ï, ƯÈ÷ ±âÁ¸ÀÇ È­Çпä¹ýÀ̳ª ¹æ»ç¼± ¿ä¹ý¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â ȯÀÚÀÇ Ä¡·á¿¡ Å« ¼º°øÀ» °ÅµÎ°í ÀÖ½À´Ï´Ù. Á¾¾çÇлӸ¸ ¾Æ´Ï¶ó ¼¼Æ÷ Ä¡·á´Â ´Ù¹ß¼º °æÈ­ÁõÀ̳ª ·ù¸¶Æ¼½º °üÀý¿°°ú °°Àº ÀÚ°¡¸é¿ª ÁúȯÀÇ °ü¸®¿¡¼­µµ ¸é¿ª ü°è¸¦ Á¶ÀýÇϰí ÀçÇÁ·Î±×·¡¹ÖÇÏ¿© À¯ÇØÇÑ ¿°Áõ ¹ÝÀÀÀ» ¾ïÁ¦ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â µî ºñ¾àÀûÀÎ ¹ßÀüÀ» °ÅµìÇϰí ÀÖ½À´Ï´Ù. Àç»ýÀÇÇп¡¼­´Â ¼Õ»óµÈ Á¶Á÷ÀÇ ±â´ÉÀ» ȸº¹½ÃŰ´Â Áٱ⼼Æ÷ Ä¡·á¹ýÀÌ °³¹ßµÇ¾î ½ÉºÎÀü, ô¼ö ¼Õ»ó, ½Å°æ ÅðÇ༺ Áúȯ µîÀÇ Ä¡·á °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº Á¶Á÷À» º¹±¸ÇÏ´Â °Í»Ó¸¸ ¾Æ´Ï¶ó Áúº´ÀÇ ¿øÀÎÀÌ µÇ´Â ±Ùº»ÀûÀÎ ¼¼Æ÷ °áÇÔÀ» ÇØ°áÇÔÀ¸·Î½á Àå±âÀûÀÌ°í °æ¿ì¿¡ µû¶ó¼­´Â ¿µ±¸ÀûÀÎ ÇØ°áÃ¥À» Á¦°øÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ¼¼Æ÷ Ä¡·á´Â ´Ü¼øÈ÷ Áõ»óÀ» Ä¡·áÇÏ´Â °Í»Ó¸¸ ¾Æ´Ï¶ó ¼¼Æ÷ ¼öÁØ¿¡¼­ ¼Õ»óµÈ Á¶Á÷À» ´ëüÇϰųª º¹±¸ÇÒ ¼ö ÀÖÀ¸¹Ç·Î º¹ÀâÇÏ°í ¸¸¼ºÀûÀ̸ç ÀÌÀü¿¡´Â Ä¡·áÇÒ ¼ö ¾ø¾ú´ø Áúº´¿¡ ´ëÇÑ È¹±âÀûÀÎ Ä¡·á¹ýÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ¾î¶»°Ô ¼¼Æ÷ Ä¡·áÀÇ Çõ½ÅÀ» ÃËÁøÇϰí Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº ¼¼Æ÷ Ä¡·áÀÇ Áøº¸¸¦ ºü¸£°Ô °¡¼ÓÈ­ÇÏ¿© ´Ù¾çÇÑ Áúº´¿¡ ´ëÇØ º¸´Ù È¿°úÀûÀ̰í, È®Àå °¡´ÉÇϸç, ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ CRISPR-Cas9¸¦ ÀÌ¿ëÇÑ À¯ÀüÀÚ ÆíÁýÀº Ä¡·á ´É·ÂÀ» Çâ»ó½Ã۱â À§ÇØ ¼¼Æ÷¸¦ Á¤È®ÇÏ°Ô º¯Çü½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â CAR-T Ä¡·á¿¡ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀ» ÁÙÀ̸鼭 ƯÁ¤ ¾Ï¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î »ï´Â È¿°úÀûÀÎ T¼¼Æ÷¸¦ »ý¼ºÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. À¯Àü°øÇлӸ¸ ¾Æ´Ï¶ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º°ú ÀÚµ¿È­ÀÇ ¹ßÀüÀ¸·Î ÅëÁ¦µÈ ȯ°æ¿¡¼­ ´ë·®ÀÇ Ä¡·á¿ë ¼¼Æ÷¸¦ »ý»êÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ³Ãµ¿º¸Á¸ÀÇ °³¼±À¸·Î Ä¡·á¿ë ¼¼Æ÷ÀÇ ÀúÀå ¹× ¿î¼ÛÀÌ ¿ëÀÌÇØÁ® Àå°Å¸® ¹× Àå±â°£ »ýÁ¸¼ºÀ» À¯ÁöÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×ÀÌ °³¹ß¿¡ Á¢¸ñµÇ¾î Á¦Á¶ °øÁ¤ÀÇ ÃÖÀûÈ­, ȯÀÚ ¹ÝÀÀ ¿¹Ãø, Ä¡·á ¼ºÀû Çâ»ó¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¼¼Æ÷ Ä¡·áÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» ³ôÀÏ »Ó¸¸ ¾Æ´Ï¶ó Èñ±Í À¯Àü¼º ÁúȯºÎÅÍ ³ëÈ­ °ü·Ã Áúȯ¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.

¼¼Æ÷Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼¼Æ÷Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ¸¸¼ºÁúȯ ¹× º¹ÇÕÁúȯÀÇ À¯º´·ü Áõ°¡, ±â¼ú ¹ßÀü, °³ÀθÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ ¿äÀÎ Áß Çϳª´Â ¾Ï Ä¡·á¿¡¼­ CAR-T¿Í °°Àº Ä¡·áÀÇ ¼º°øÀ¸·Î, CAR-T´Â ´Ù¸¥ Ä¡·á¹ýÀÌ ½ÇÆÐÇÑ È¯ÀÚ¿¡°Ô Áö¼ÓÀû À̰í È¿°úÀûÀÎ ¹ÝÀÀÀ» º¸ÀÌ´Â ¼¼Æ÷ Ä¡·áÀÇ Å« ÀáÀç·ÂÀ» º¸¿©ÁÖ¾ú½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ´Ù¸¥ À¯ÇüÀÇ ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, À¯Àü¼º Áúȯ¿¡ Àû¿ëÀ» È®´ëÇϱâ À§ÇÑ ÅõÀÚ¿Í ¿¬±¸°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ À¯ÀüÀÚ ÆíÁý°ú ¹ÙÀÌ¿À Á¦Á¶ ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ °³¹ß ¹× ±Ô¸ð È®´ë°¡ ¿ëÀÌÇØÁ® ºñ¿ë Àý°¨°ú Á¢±Ù¼º °³¼±ÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Ä¡·á¹ýÀº ½ÉºÎÀü, ´ç´¢º´, ½Å°æÅðÇ༺ Áúȯ µîÀ» Ä¡·áÇϱâ À§ÇØ °³¹ßµÇ°í ÀÖÀ¸¸ç, ½ÃÀå °³¹ß¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ °³ÀθÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ȯÀÚ °³°³Àο¡°Ô ¸ÂÃãÈ­µÈ È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ¼¼Æ÷Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¼ÒºñÀÚÀÇ ³ô¾ÆÁø Àνİú ±âÁ¸ÀÇ Á¦¾àÀû Á¢±Ù¹ýÀ» ³Ñ¾î¼± Áøº¸µÈ ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ ¿å±¸¿¡ ÀÇÇØ °­È­µÇ°í ÀÖ½À´Ï´Ù. ȹ±âÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ º¸´Ù ½Å¼ÓÇÑ ½ÂÀÎ °æ·Î¸¦ Æ÷ÇÔÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øµµ ¼¼Æ÷ ±â¹Ý Ä¡·á¹ýÀÇ °³¹ß°ú äÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸, Á¦Á¶ ´É·Â, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©ÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î ¼¼Æ÷Ä¡·áÁ¦ ½ÃÀåÀº ÇâÈÄ ¼ö³â°£ Áö¼ÓÀûÀÎ ¼ºÀå¼¼¸¦ º¸ÀÌ¸ç ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ¿©°ÇÀÌ Á¶¼ºµÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä¡·á(µ¿Á¾ À̽Ä, ÀÚ°¡ À̽Ä);¿ëµµ(Á¶»ç, ÀÓ»ó)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 183°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Cell Therapy Market to Reach US$42.1 Billion by 2030

The global market for Cell Therapy estimated at US$19.1 Billion in the year 2024, is expected to reach US$42.1 Billion by 2030, growing at a CAGR of 14.1% over the analysis period 2024-2030. Allogenic Cell Therapy, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$23.4 Billion by the end of the analysis period. Growth in the Autologous Cell Therapy segment is estimated at 15.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.3 Billion While China is Forecast to Grow at 13.5% CAGR

The Cell Therapy market in the U.S. is estimated at US$5.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 13.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.1% and 11.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.3% CAGR.

Global Cell Therapy Market - Key Trends and Drivers Summarized

What Makes Cell Therapy a Game-Changer in Modern Medicine?

Cell therapy is dramatically reshaping the medical field by using the body’s own cells to treat and repair damaged tissues, providing innovative solutions for a wide array of diseases, including cancer, autoimmune disorders, and degenerative conditions. Unlike traditional treatments that often focus on managing symptoms, cell therapy aims to address the root cause of diseases by harnessing living cells that can be engineered or harvested to target specific biological mechanisms. For instance, CAR-T cell therapy has been a breakthrough in oncology, where a patient’s T cells are genetically engineered to seek out and destroy cancer cells. This form of therapy has already shown remarkable success in treating certain types of blood cancers and is expanding into other cancer types. In regenerative medicine, stem cell therapy is being used to repair tissues damaged by heart disease, neurodegenerative disorders, and diabetes. These therapies represent a significant leap forward in personalized treatment, offering hope for patients with diseases that were once considered untreatable. As research progresses, cell therapy is becoming a central pillar in the future of personalized medicine, offering tailored treatments that align with a patient’s unique genetic and cellular makeup.

How Is Cell Therapy Changing the Way Complex Diseases Are Treated?

Cell therapy is crucial for treating complex diseases that do not respond well to traditional treatments, offering new avenues for therapeutic intervention. In the field of oncology, cell-based treatments like CAR-T therapy have revolutionized cancer treatment by using a patient’s own immune cells to target and kill cancerous cells. This highly personalized approach to therapy has shown great success in treating cancers such as leukemia and lymphoma, especially in patients who have not responded to conventional chemotherapy or radiation. Beyond oncology, cell therapy is making strides in managing autoimmune diseases like multiple sclerosis and rheumatoid arthritis, where it helps to modulate and reprogram the immune system, reducing harmful inflammatory responses. In regenerative medicine, stem cell therapies are being developed to restore function to damaged tissues, offering potential cures for conditions like heart failure, spinal cord injuries, and neurodegenerative diseases. These therapies not only aim to repair tissues but also to provide long-term, possibly permanent, solutions by addressing the underlying cellular deficiencies that cause disease. Cell therapy’s ability to replace or restore damaged tissues at a cellular level, rather than merely treating symptoms, makes it a game-changer for complex, chronic, and previously untreatable diseases.

How Are Technological Advances Driving Innovation in Cell Therapy?

Technological advancements are rapidly accelerating progress in cell therapy, making it more effective, scalable, and accessible for a variety of diseases. One of the most transformative technologies has been gene editing, particularly with CRISPR-Cas9, which allows for precise modifications of cells to enhance their therapeutic potential. This has revolutionized CAR-T therapies, enabling scientists to engineer T cells that are highly effective at targeting specific cancer cells, while reducing potential side effects. Beyond genetic engineering, advancements in bioprocessing and automation are making it possible to produce large quantities of therapeutic cells in a controlled environment, which is critical as these therapies move from clinical trials to wider market availability. Additionally, improvements in cryopreservation have made it easier to store and transport therapeutic cells, maintaining their viability across long distances and extended periods, which has helped expand the reach of these treatments to more regions globally. Furthermore, artificial intelligence (AI) and machine learning are being integrated into cell therapy development, helping to optimize the manufacturing process, predict patient responses, and improve treatment outcomes. These technological breakthroughs are not only enhancing the precision and efficiency of cell therapies but are also broadening their applications to treat a wider range of diseases, from rare genetic disorders to age-related conditions.

What Factors Are Propelling the Growth of the Cell Therapy Market?

The growth in the cell therapy market is driven by several factors, including the increasing prevalence of chronic and complex diseases, technological advancements, and the rising demand for personalized treatments. One of the most significant drivers is the success of therapies like CAR-T in cancer treatment, which has demonstrated the immense potential of cell therapies to provide durable and effective responses in patients who have exhausted other treatment options. This has led to a surge in investment and research aimed at expanding cell therapy applications to other types of cancer, autoimmune diseases, and genetic disorders. Technological advancements, particularly in gene editing and biomanufacturing, are making it easier to develop and scale these therapies, driving down costs and improving access. The field of regenerative medicine is another major contributor, as therapies using stem cells are increasingly being developed to treat diseases such as heart failure, diabetes, and neurodegenerative disorders, further fueling market growth. Additionally, the growing focus on personalized medicine is spurring demand for cell therapies that can be tailored to individual patients, offering more targeted and effective treatment options. This trend is reinforced by increasing consumer awareness and the desire for advanced, cutting-edge therapies that go beyond traditional pharmaceutical approaches. Regulatory support, including faster approval pathways for breakthrough therapies, is also encouraging the development and adoption of cell-based treatments. With continuous advancements in research, manufacturing capabilities, and regulatory frameworks, the cell therapy market is poised for sustained growth in the coming years, offering transformative treatment options for a wide range of diseases.

SCOPE OF STUDY:

The report analyzes the Cell Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Allogenic, Autologous); Application (Research, Clinical)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 183 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â